A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)
Overcoming drug resistance in metastatic castration-resistant prostate cancer with novel combination of TGF-ß receptor inhibitor LY2157299 and enzalutamide: a randomized multi-site phase II study
EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response.
J19138 - A Phase I/II Study of Regorafenib and Pembrolizumab in Metastatic Colorectal Cancer Patients in 3rd and 4th line setting